Humanigen Signs Agreement With MD Anderson Cancer Center to Begin Research Investigating Lenzilumab as CAR-T Support
April 16, 2018 07:00 ET
|
Humanigen, Inc
BRISBANE, Calif., April 16, 2018 (GLOBE NEWSWIRE) -- Humanigen, Inc. (OTCQB:HGEN), a biopharmaceutical company pursuing cutting-edge science to develop its proprietary monoclonal antibodies for...
Humanigen Completes Enrollment of Phase 1 Clinical Trial of Lenzilumab for Treatment of Chronic Myelomonocytic Leukemia
March 15, 2018 07:00 ET
|
Humanigen, Inc
BRISBANE, Calif., March 15, 2018 (GLOBE NEWSWIRE) -- Humanigen, Inc. (OTCQB:HGEN), a biopharmaceutical company pursuing cutting-edge science to develop its proprietary monoclonal antibodies for...
Humanigen Appoints Robert Savage to Board of Directors
March 12, 2018 07:00 ET
|
Humanigen, Inc
BRISBANE, Calif., March 12, 2018 (GLOBE NEWSWIRE) -- Humanigen, Inc. (OTCQB:HGEN), a biopharmaceutical company pursuing cutting-edge science to develop its proprietary monoclonal antibodies for...
Humanigen CEO to Present at Inaugural LD Micro Virtual Conference
March 01, 2018 16:15 ET
|
Humanigen, Inc
BRISBANE, Calif., March 01, 2018 (GLOBE NEWSWIRE) -- Humanigen, Inc. (OTCQB:HGEN), a biopharmaceutical company pursuing cutting-edge science to develop its proprietary monoclonal antibodies for...
Humanigen Completes Exchange of Loan Obligations for Equity
February 27, 2018 16:05 ET
|
Humanigen, Inc
Company Transformation Continues, Focused on Making CAR-T Safer, Better, More Routine Lenzilumab Nears Start of Clinical Testing to Prevent Critical CAR-T-related Neurotoxicity BRISBANE, Calif.,...
Humanigen Appoints Rainer Boehm, M.D., to Board of Directors
February 07, 2018 07:00 ET
|
Humanigen, Inc
BRISBANE, Calif., Feb. 07, 2018 (GLOBE NEWSWIRE) -- Humanigen, Inc. (OTCQB:HGEN), a biopharmaceutical company pursuing cutting-edge science to develop its proprietary monoclonal antibodies for...
Humanigen CEO to Present at NobleCon14, BIO CEO Investor Conferences
January 25, 2018 08:00 ET
|
Humanigen, Inc
BRISBANE, Calif., Jan. 25, 2018 (GLOBE NEWSWIRE) -- Humanigen, Inc. (OTCQB:HGEN), a biopharmaceutical company pursuing cutting-edge science to develop its proprietary monoclonal antibodies for...
Humanigen Signs Definitive Agreements to Exchange Loan Obligations for Equity
December 21, 2017 16:45 ET
|
Humanigen, Inc
Transactions Create Biotechnology Company Focused on Immunotherapy and Oncology Lenzilumab Begins Development for Treating Key Side-Effects Associated with CAR-T BRISBANE, Calif., Dec. 21, 2017 ...
Humanigen Appoints Chief Financial Officer
August 28, 2017 08:00 ET
|
Humanigen, Inc
BRISBANE, Calif., Aug. 28, 2017 (GLOBE NEWSWIRE) -- Humanigen, Inc. (OTCQB:HGEN), a biopharmaceutical company focused on advancing medicines for patients with neglected and rare diseases, today...
Humanigen Announces up to $15 Million Committed Equity Financing Facility
August 24, 2017 08:30 ET
|
Humanigen, Inc.
BRISBANE, Calif., Aug. 24, 2017 (GLOBE NEWSWIRE) -- Humanigen, Inc. (OTCQB:HGEN), a biopharmaceutical company focused on advancing medicines for patients with neglected and rare diseases, today...